Sewon Cellontech Registers Indian Patent for High-Concentration Medical 'Bio Collagen'

[Asia Economy Reporter Yoo Hyun-seok] Sewon Cellontech announced on the 16th that it has completed patent registration in India for its high-concentration medical (biomaterial) collagen (hereinafter referred to as ‘BioCollagen’) manufacturing technology.

The patent relates to technology for manufacturing ‘BioCollagen’ that ensures ▲biological safety and sterility ▲high concentration and high purity quality for use as medical materials.

Based on the patent, through a multi-step strict process including extraction, purification, concentration, and mixing using precision filtration and tangential flow filtration (concentration after removal of low molecular substances), ‘BioCollagen’ of solid quality can be obtained. In particular, the ‘BioCollagen’ manufactured by the patented method is characterized by maintaining the unique properties and structure of collagen existing in the body.

This ‘BioCollagen’ is used as a raw material for manufacturing various forms (liquid, sponge, powder) of regenerative medical products with excellent ▲biocompatibility ▲safety ▲tissue regeneration capability.

Seo Dong-sam, Head of the Regenerative Medical System Innovation Center at Sewon Cellontech, explained, “This is an upgraded technology of the original technology for manufacturing and productizing BioCollagen, for which Sewon Cellontech has secured global patents in the US, Europe, China, and other regions,” and added,

With the acquisition of the Indian patent rights, “We have upgraded the excellence of ‘BioCollagen’ not only in terms of ▲technical performance that enhances the performance of regenerative medical products, but also in terms of ▲industrial applicability enabling productization in various formulations, and ▲marketability by establishing a foundation for expanding entry into India, an emerging market for regenerative medicine, and the broad biomaterials field,” he emphasized.

Meanwhile, Sewon Cellontech is expanding infrastructure to respond to the global demand expansion of ‘BioCollagen’ based on RMS CAMP being constructed in Geumgok General Industrial Complex (located in Namyangju-si, Gyeonggi-do), along with the expansion of patent technology development.

Sewon Cellontech independently developed and is supplying domestically and internationally 10 items of RegenGraft, a therapeutic material used for treating various damaged human tissues, using ‘BioCollagen’ (a raw material drug registered with the US Food and Drug Administration (FDA)) as the raw material. It has also exported it as a raw material for developing ▲artificial corneas ▲tissue fillers ▲cell culture scaffolds ▲cosmetic and plastic fillers to global biopharmaceutical companies.

This content was produced with the assistance of AI translation services.